Biomarker ID | 431 |
PMID | 19242826 |
Year | 2010 |
Biomarker | TMPRSS2 |
Biomarker Basis | Expression Based |
Biomolecule | mRNA |
Source | Tissue |
Subjects | Humans |
Regulation | Upregulated (Clinical Stage 1&2: 3.43 ± 0.62 ; Vs Clinical Stage 3: 5.45 ± 0.92) |
Odds Ratio/Hazard Ratio/Relative Risk | NA |
Effect on Pathways | Pathways Include:- Androgen receptor regulation of biosynthesis and transcription,Androgen receptor proteolysis and transcription regulation |
Experiment | Clincal Stage (1-2) Vs Clinical Stage 3 |
Type of Biomarker | Prognostic |
Cohort | Out of 63 patients, 39 had Clinical stages (1-2) and 24 had Stage 3. |
Senstivity | NA |
Specificity | NA |
AUC | NA |
Accuracy | NA |
Level Of Significance | p=0.02 |
Method Used | qRT-PCR |
Clinical | No |
Remarks | Results were then normalized using the ratio of TMPRSS2/ b-actin and KLK11/b-actin concentration for each sample |
Clinical Trial Number | NA |
Degree Of Validity | Not validated on independent patient dataset |
Technical Name | TMPRSS2 |